Sanofi, a French health care company, announced Tuesday it will acquire Protein Sciences Corp., the Meriden-based vaccines biotech company, for up to $750 million.

David Loew, Sanofi executive vice president and head of Sanofi Pasteur, Sanofi’s vaccines division, said the acquisition will allow it to broaden its flu vaccine portfolio.

The transaction gives Sanofi the Flublok® vaccine developed by Protein Sciences. Unlike traditional shots, it’s not grown in eggs and can be produced to adjust to mutations in the flu virus.

Hartford Courant story
Reuters story